We are live on ! Find out more

PVLA

Palvella Therapeutics

PVLA

Market cap $2.18B

151.22 USD

-0.47

0.31%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

151.20

-0.02

0.01%

1 day

-0.31%

5 days

2.69%

1 month

-1.5%

3 months

29.79%

6 months

19.97%

Year to date

50.8%

1 year

176.81%

5 years

-66%

10 years

20.4%

About: Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

Employees: 29

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 26.7%

Neutral 73.3%

Negative 0%

Palvella Therapeutics Appoints James R. Treat, M.D.

Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas

Palvella Therapeutics Appoints James R. Treat, M.D.

Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences

WAYNE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in two upcoming healthcare investor conferences.

Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences

Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and establish a new standard of care for an estimated more than 30,000 pediatric and adult patients living with microcystic lymphatic malformations in the U.S.

Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheel

Palvella advances QTORIN rapamycin, targeting microcystic lymphatic malformations, with positive Phase 3 SELVA data and a rolling NDA submission underway. PVLA leverages a repeatable regulatory and commercial platform, aiming to expand QTORIN across multiple mTOR-driven dermatological indications, supporting a multi-indication commercial flywheel. Strong liquidity from a recent $230M equity raise enables PVLA to invest in commercialization and pipeline expansion, mitigating typical small biotech funding risks.

Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheel

Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands

Palvella Therapeutics NASDAQ: PVLA is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN rapamycin, moving toward a planned New Drug Application submission for microcystic lymphatic malformations.

Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands

Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

WAYNE, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 3:30 p.m. ET.

Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcript

Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcript

Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcript

Palvella Therapeutics Q2 Earnings Call Highlights

Palvella Therapeutics NASDAQ: PVLA said it remains on track to complete its new drug application submission for QTORIN rapamycin in microcystic lymphatic malformations, or mLM, during the second half of 2026, with potential FDA approval targeted for the first half of 2027.

Palvella Therapeutics Q2 Earnings Call Highlights

Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA submission on track for the second half of 2026 Preparing for a planned standalone U.S. commercial launch of QTORIN™ rapamycin for microcystic lymphatic malformations in the first half of 2027, if approved Initiation of Phase 3 trial of QTORIN™ rapamycin for the treatment of cutaneous venous malformations planned for the fourth quarter of 2026 Initiation of Phase 2 trial of QTORIN™ pitavastatin for the treatment of disseminated superficial actinic porokeratosis planned for the second half of 2026 Topline results from the Phase 2 LOTU trial of QTORIN™ rapamycin for clinically significant angiokeratomas expected in the second half of 2027 Cash, cash equivalents and short-term investments of $250.6 million as of June 30, 2026 Company to host conference call at 8:30 a.m. ET today WAYNE, Pa.

Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing

Hybrid public meeting on August 5th will explore approaches to selecting and prioritizing promising FDA-approved drugs for repurposing, with the potential to accelerate patient access to effective therapies for significant unmet medical needs

Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing

See News Rankings

Price charts implemented using Lightweight Charts™